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Sickle Cell Disease is a collection of genetically inherited disorders of red blood cells 
affecting millions of people in the whole world. In the United States, it affects people of all 
ethnic/racial descent. It is usually diagnosed during early childhood. It is a significant public health 
concern for both the affected individuals and their surrounding community because it is expensive 
to manage and it has detrimental effects on people’s lives and livelihood. Research on the best 
treatment for Sickle Cell Disease is still underway in several healthcare and research facilities. 
Currently, there is no up-to-date documentation of Sickle Cell Disease centers in the United States 
of America. This study aims to provide up-to-date information on the location and distribution of 
Sickle Cell Disease Centers in the US and to improve the public’s healthcare access by providing 
resources that will ease referral and search for Sickle Cell Disease centers by both the healthcare 
workers and patients with sickle cell disease. 
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The Centers for Disease Control and Prevention (CDC) describes sickle cell disease (SCD) 
as a collection of inherited red blood cell disorders that cause the red blood cells (RBCs) that are 
normally round and smooth to become hard, sticky, and sickled.1 These malformed cells clog small 
blood vessels, causing the patients with SCD significant pain and other problems like infection, 
end organ failure and stroke.1,2 Sickle cell disease exhibits an autosomal recessive mode of 
inheritance1 and affects males and females equally.3 In the United States (US), it is usually 
diagnosed during early childhood, most often on newborn screening.4 
The different genotypes of SCD are categorized based on the different combinations of 
abnormal hemoglobin. There are three types of hemoglobin in the human body that play a major 
role in gaseous exchange;5 Hemoglobin A (HbA), also known as the adult hemoglobin, is the most 
common type, and it accounts for about 97% of hemoglobin present in a normal adult. It is encoded 
by HBA1, HBA2 and HBB genes, and each of its four subunits consists of two alpha (󠇋α) and two 
beta(󠇋β) subunits.6 Hemoglobin A2 (HbA2), also known as minor variant of adult hemoglobin , 
accounts for about 2% of hemoglobin, and its subunits consist of two α and two delta (󠇋δ) subunits.6 
Hemoglobin F (HbF), also known as fetal hemoglobin, is usually present at levels of 65 to 90% in 
a newborn baby but drops in concentration to less than 2% when the baby is 6 months to 12 months 
of age. 6,7,8 It consists of two α and two gamma (󠇋γ) subunits. The two gamma subunits enable HbF 
to have higher affinity for oxygen compared to the other two types of Hb, HbA and HbA2.8,6 
Hemoglobin S (HbS) is the cause of sickle cell disease and an allelic variant of the β-globin 
gene whose formation occurs as a result of a point mutation on the β-globin gene on chromosome 
11.2 (See Appendix Figure 1 in Appendix D) The molecular basis of this disease is such that it 
 
 2 
occurs in the first exon of the gene, resulting in glutamic acid being replaced by valine at the sixth 
codon position of the β-globin polypeptide chain body (Glu6Val).9 
Signs and symptoms in people with SCD vary from one person to another and can be 
categorized in two groups: acute and chronic complications. Acute complications occur within a 
short time span, and the most common is an acute vaso-occlusive crisis that results from tissue 
ischemia caused by blockage of tiny blood vessels most commonly in bones and bone marrow. 
Other acute complications include infection that result in fever, acute kidney injury (AKI), acute 
anemia, acute chest syndrome (ACS), priapism, acute stroke, hepatobiliary complications, splenic 
sequestration and acute eye problems. Chronic complications affect almost any organ and are 
mostly because of  prolonged acute complications.10 Patients with SCD who have high HbF levels 
have less severe clinical presentation and mild complications because higher levels of HbF inhibits 
polymerization of sickle Hemoglobin (HbS).7 
Sickle cell trait (SCT) is a condition in which an individual inherits one sickle cell gene 
variant from one parent and one normal hemoglobin gene variant from the other parent. Most 
individuals with SCT do not exhibit any signs of SCD and they live a normal life, but in rare cases 
some experience some complications. Environmental conditions like high atmospheric pressure, 
dehydration, high altitude levels and low oxygen levels can trigger the complications in SCT.4 
SCD is a significant public health concern for both the affected individuals and their 
surrounding community. Non-specialized care of patients with SCD exposes them to the 
possibility of inadequate management due to lack of up-to-date information on the management 
of the condition as compared to receiving care for their condition in SCD specialized healthcare 
facilities. This study will provide up–to-date information on location and distribution of SCD 
treatment and research centers in the US. The result of this study will be used to develop a resource 
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map to guide researchers and clinicians on where to refer patients with SCD and to aid patients 
living with SCD in locating centers offering services in their area. 
1.1 SPECIFIC AIMS 
1.1.1 Specific Aim 1 
Identify the number and precise location of SCD centers in the US and the population they 
serve in each state. 
1.1.2 Specific Aim 2 
Use the results on the SCD centers distribution to evaluate the demographic characteristics 
of the counties where the centers are located and to identify the proportion of individuals with 
“ease of access” to the SCD centers. 
1.1.3 Specific Aim 3 
Develop a resource map to guide researchers and clinicians on where to refer patients with 
SCD and to aid patients living with SCD in locating centers offering services in their area. 
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2.0 REVIEW OF LITERATURE 
Globally, people originating from regions that experience endemic malaria are more 
probable to have the sickle cell trait. These regions include Africa, India, the Mediterranean and 
Saudi Arabia.2,11 The sickle-cell trait enhances resistance to falciparum malaria in early childhood 
resulting in the sickle-cell gene being common in Africa; therefore, children with the SCT survive, 
promoting genetic transmission of the abnormal hemoglobin gene.2 SCD, however, does not confer 
this type of protection, making Malaria a major cause of ill-health and death in children with sickle-
cell anemia, the most severe type of SCD, in Africa.11 The Sickle Cell Disease Coalition (SCDC) 
estimates that approximately 1,000 children are born with sickle cell disease daily in Africa,18 but 
unfortunately, more than half of them die before attaining the age of five years. In resource poor 
countries, 90% of the children suffering from sickle cell disease do not live to adulthood.12 SCD 
has contributed a considerable proportion to the number of deaths in children below the age of 5 
years, mainly following delayed diagnosis, educational gaps among service providers on best 
measures of managing the patients, and poor access to appropriate treatment and treatment 
facilities.13  
The Sickle Cell Disease Coalition predicts that by 2050 there will be a 30% growth in the 
number of patients diagnosed with sickle cell disease globally,12 due to a decrease in mortality 
suggested by the report received by CDC of a shift in the age at death in SCD patients in the year 
2006.12  
In the United States, more than 2 million people carry the sickle cell gene variant.3 African 
Americans are known to have a higher SCD prevalence with gene frequencies of 4% for HbS, 
1.5% for HbC and 4% for beta thalassemia,14 as compared to other racial/ethnic groups.15,16,17 
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Current population-based estimates suggest that 1 out of every 365 African American births and 1 
out of every 16,300 Hispanic births have SCD.1,18 One in every 13 Black or African-American 
children (approximately 8%) is born with the sickle cell trait, and about 300,000 individuals in 
America have the sickle cell trait.18 
Hassel KL (2010) estimated that SCD affects about 100,000 people in the USA19 with a 
majority of them being of African American descent,3 and more than 30,000 of them being 
homozygous for HbS disease.3 The American Society of Hematology states that approximately 
2,000 incident cases of SCD are detected yearly through newborn screening.18 The severity of SCD 
largely depends on an individual patient’s genotype.2  Sickle cell anemia, which entails both 
genotypes HbSS and HbSβ0, is the most severe and commonly occurring20,21 SCD genotype in the 
US with an expected prevalence of 1 in every 625 newborn babies.3 Patients with SCA have 
mutations that cause HbSS and HbSβ0thal. All people who are either homozygous (HbSS) or 
compound heterozygous for an HbS allele and another variant hemoglobin type such as Hgb C, 
Hb D, Hb Oarab and βthal manifest some clinical symptoms of SCD which include hemolytic 
anemia, significant episodes of pain and multiple organ damage.22 
Patients with Sickle Hemoglobin-C (HbSC) Disease have an additional gene mutation that 
produces hemoglobin C in addition to hemoglobin S. The incidence ratio is 1:7386 newborn babies 
screened in the US.20 Patients with HbSC disease experience less anemia compared to those with 
HbSS due to a higher red blood cell count. Individuals with West African, Mediterranean and 
Middle Eastern origin experience a high frequency of this SCD genotype.23,24 
In Sickle Beta Thalassemia, the severity of sickle cell disease depends on the amount of 
beta globin produced. 20 Patients with Sickle Beta-0 Thalassemia (HbSβ0thal) do not produce beta 
globin, therefore resulting in no protein translation and symptoms resembling those of individuals 
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with HbSS with the presence of abnormally small erythrocytes. Those with Sickle Beta-plus 
Thalassemia (󠇋HbSβ+thal) have a decreased amount of beta globin proteins, and symptoms are 
milder than Sickle Cell Anemia (SCA). Sickle Beta Thalassemia is seen most commonly in people 
of the Mediterranean and Caribbean origin.22 
Individuals of Asian and Latin American origins25 more commonly have Sickle 
Hemoglobin D disease (HbSD) and they experience a moderately severe type of anemia with 
occasional pain episodes. Patients with Sickle Hemoglobin Oarab disease (HbSOarab) can have 
symptoms and complications similar to those with HbSS; the most common being joint pains, 
malaise, anemia and occasional jaundice with distinctive plasma proteins disturbances.26 It mostly 
affects people with Arabian, North African and Eastern Mediterranean origin.25 These and 
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Figure 1 Types and Categorization of Sickle Cell Disease 
 
 8 
2.1 HEALTHCARE ACCESS 
 
The SCD comprehensive centers are not supported with federal funding , as a result of low 
insurance payments for clinical services, they therefore often rely on financial support from 
hospital systems and other institutions.27 
Bemrich-Stolz CJ, et al (2015) assessed transition care in adult patients with SCD and  
stated that adult patients face challenges in attempting to establish access to care because of 
difficulty identifying new adult providers, and challenges concerning transportation due to the 
distance and expenses they incur to get to the healthcare facilities.28 As per several other studies, 
a number of adult sickle cell disease patients opt to try different techniques at home in an attempt 
to treat themselves, mostly for pain crisis, in preference to going to health care facilities because 
of little confidence and diminished trust in the primary care and adult emergency departments.27,28 
Several of the patients stated that the Emergency room (ER) physicians treated them as “drug 
seekers” and not patients. Other patients stated that following the opioid crisis, physicians were 
unwilling to prescribe them a sufficient amount of analgesic medications to treat their pain during 
a crisis at home and as a result they end up visiting the ER often for additional pain 
management.27,28,29,30,31 
Patients with SCD who live a significant distance away from the SCD specialty centers or 
live in rural areas or in areas with bad terrain, poor infrastructure and/or poor public transportation 
services have a hard time keeping up with their clinic appointments. The use of telehealth and 
telemedicine results in improvement in medication adherence, the number of clinic visits by the 
patients, and patient satisfaction.32,33 
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2.2 FINANCES, FUNDING AND SUPPORT 
 
The financial stability of patients with SCD is affected due to loss of jobs following 
frequent absenteeism from work caused by the patients developing frequent sickle cell disease 
complications, more especially the pain crisis. As a result of loss of jobs, they end up lacking 
insurance to be able to pay for their hospital visits and medication refills.28 Even though a majority 
of people with SCD are able to obtain insurance through Medicaid, they still may not be able to 
access the healthcare services they need.27,34 The social life and relationships of patients with SCD, 
both at work and at home, are also affected. Patients with SCD feel like they receive less support 
from other members of their families, except their mothers, who they believe understand their pain 
and situation.28 
The National Sickle Cell Disease Control Act (Public Law 92-294), that allowed the 
establishment of programs to provide several services for patients with SCD was first passed by 
the US Congress in 1972. It provided the opportunity to start informational, educational, screening, 
research, testing, counseling and treatment programs.35  Three major agencies were responsible 
for the program on the federal level: 1) The CDC developed hemoglobinopathy laboratories and 
training programs to provide proficiency testing and to serve as a reference laboratory, 2) The 
Health Services Administration (HSA) developed sickle cell screening and education clinics and 
3) The National Institute of Health (NIH) developed comprehensive sickle cell centers whose main 
aim was to perform research and treatment of SCD.35 In those initial years of establishment, the 
NIH was the body administering the sickle cell program in the sickle cell centers with well set and 
defined goals which were “1) to reduce the number of individuals getting sick and those dying 
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from sickle cell disease, 2) to educate the public about the disease and to increase knowledge about 
it, and 3) to invent and assess new ways of treatment of sickle cell disease.”35 
In 2004, after the approval of the American Jobs Creation Act of 2004 (Public Law 108-
357) that included funding specifically for SCD, there was a great buildup of SCD research and 
treatment. Unfortunately the appropriations for the program lapsed in 2009 after a duration of five 
years and has never been reauthorized again.36 
Funding for both research and treatment centers is a big challenge for the institutions 
working on SCD. Farook Faheem et al in a cross-sectional study carried out in 2020 compared 
research funding for SCD and Cystic fibrosis (CF) from 2008 to 2017 using the NIH report 
database. They found that number of per annual PubMed publications was initially similar for CF 
and SCD, but later the CF research output expanded at a faster rate. Publications of CF remained 
greater than those of SCD between 2008 to 2018, (mean [SD] publications, 1594 [225] vs 926 
[157]; P < .001) and benevolent disbursement of funds from foundations were significantly higher 
per individual with CF in comparison to funding per individual with SCD (mean [SD], $ 7690 
[$3974] vs $102 [$13.7]; P < .001).27 Cystic fibrosis (CF) is an inherited disease with an autosomal 
recessive mode of inheritance like SCD, but CF largely affects white individuals (1 in 2500) while 
SCD primarily affects black individuals (1 in 365). These are evidentially racially aligned diseases, 
and the fact that CF is receiving more funding and patients with the condition are receiving more 
financial support in relation to treatment than those with SCD expose health funding inequities 
that may be driven by social determinants such as race. There is need for change and equality.31 
The 115th congress passed the [S.2465] Sickle Cell Disease and Other Heritable Blood 
Disorders Research, Surveillance, Prevention, and Treatment Act of 2018, and it was signed into 
law by the president on December 18, 2018. Therefore through this act, the Department of Health 
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and Human services is authorized to provide funding to support collection of data on SCD and 
other heritable blood disorders by government, educational and nonprofit organizations .37 It had 
appeared in forms that were almost similar in the Sickle Cell Disease Research, Surveillance, 
Prevention, and Treatment Act of 2015 (HR 1807, 114th Congress) and the Sickle Cell Disease 
Research, Surveillance, Prevention, and Treatment Act of 2014 (HR 5124, 113th Congress).36 
2.3 TREATMENT OF SICKLE CELL DISEASE 
Prompt recognition and consistent medical care to reduce and stop complications result in 
improvement of well-being in individuals with SCD. SCD is a lifelong illness that has widely 
varying severity from one individual to another.38 
2.3.1 Current Recommendations 
The National Heart, Lung, and Blood Institute (NHLBI) states that “a patient with SCD in 
painful crisis should be treated as an emergency and should undergo a thorough history and 
physical examination to determine whether an illness might have precipitated the pain, so that the 
cause and symptom can be treated at the same time.”39 Pain medication is given depending on an 
individual patient’s level of pain; with NSAIDs and Acetaminophen being used to manage mild to 
moderate pain while opioids, like morphine, have been used for management of moderate to severe 
pain. For better treatment results, it is important for patients, families and healthcare providers to 
be well educated on pain management.39 Penicillin is used as a prophylactic medication in children 
from when they are newborns to 5 years of age.39 All individuals with SCD have to get the 
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immunizations as per the Advisory Committee on Immunization Practices, which include 
additional recommendations for pneumococcal vaccines for individuals with SCD, unless there is 
a contraindication based on an individual’s health. Due to increased risk of individuals with SCD 
getting invasive pneumococcal disease, it is recommended that all infants with SCD should receive 
a complete dose of the 13-valent conjugate pneumococcal vaccine (PCV13) shortly after being 
born and the 23- valent pneumococcal polysaccharide vaccine (PPSV23) at the age of 2 years and 
a second dose at the age of 5 years. Adults who are more than 19 years of age with asplenia and 
have not previously received the pneumococcal vaccine should be given one dose of the PCV13 
followed by PPSV23 at least 8 weeks later.39 
Several tests are carried out in patients with SCD to rule out SCD complications like stroke 
and end organ failure. The tests include radiological and non-radiological imaging, pulmonary 
function tests and blood tests. The recommended neuroimaging test is Transcranial Doppler (TCD) 
ultrasound which is done annually in children with SCA starting at the age of 2 years and 
continuing until at least the age of 16 years. Computed tomography (CT) scans and magnetic 
resonance imaging (MRI) have very low supporting evidence of benefits in patients, of all ages, 
with SCD.10 Patients showing signs and symptoms of respiratory problems undergo the pulmonary 
function tests to establish the cause and preferred treatment for it. In patients with SCD 
experiencing Acute Renal Failure, a daily monitoring of renal function including serum creatinine 
and fluid intake/output is recommended.10 They also get blood tests like check of Hb S level and 




2.3.2 Treatment Options 
Some effective treatments exist that can reduce symptoms and prolong life.38 Hydroxyurea 
and 5-azacytidine are two medications known for boosting the presence of HbF in the blood of 
patients with SCD. 39,40 Hydroxyurea is given to stimulate HbF production, by releasing nitric 
oxide in adult patients with SCD, while 5-azacitidine inhibits DNA methylation, therefore  
preventing the switch from HbF to HbA synthesis.40 HbF helps achieve higher oxygen 
concentration in the blood of these patients due to its high affinity for oxygen, and therefore 
reduces the number of times they become hypoxic.40 
 Blood and Bone marrow transplants 
Blood and bone marrow transplants are presently the only cure for sickle cell disease, and 
only a few of people with SCD being able to receive a transplant due to hardship in finding donors 
that match with them.39 This also comes with a risk of death which the patients with SCD and their 
families have to decide upon. Blood transfusion is not recommended in patients with SCD unless 
there are other indications because it may result in iron overload in the patients.10 
 Gene Therapy for Sickle Cell Disease 
The utilization of gene therapy in the treatment of SCD is still being explored.41 Genetic 
related treatments that change an individual’s hematopoietic stem cells may provide alternative 
treatment and probably a cure for patients with SCD who are not able to find a well matched bone 
marrow donor.17 When introduced to the bloodstream, the refashioned stem cells travel to the bone 
marrow where they make healthy non-sickling red blood cells.17 
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There are several gene- editing studies that are being conducted to further study this method 
of treatment. A number of clinical trials have recruited SCD patients and are working on using 
CRISPR and stem cell therapy in modifying the affected cells.42 Some considerable achievements 
have been made at the basic level to successfully attain the genetic correction of 
hemoglobinopathies9 but there is still significant research that needs to be completed.42 
As studies and research continue, it continues to be important to offer genetic testing and 
counseling to individuals or couples with or at risk for having a child with SCD, to enable them to 
make well informed decisions on marriage and childbearing. 
2.4 MORTALITY AMONG SICKLE CELL DISEASE PATIENTS 
In the 1980s, SCD related hospitalizations and deaths were high in comparison to the late 
1990s and early 2000s where there was a remarkable decrease in early childhood mortality. In 
1975, New York was the first state to enact newborn screening for sickle cell disease43,44 and in 
2006 the Recommended Uniform Screening Panel (RUSP) that included SCD was published.44 
This mortality decrease is attributed to the recommendation of newborn screening for SCD 
that enabled early detection and management of the young patients, improved health of patients 
with sickle cell disease following the availability of penicillin prophylaxis, and administration of 
Hemophilus influenzae type B and Streptococcus pneumoniae vaccinations.2,30 Despite the 
improvement, patients with SCD of African-American ethnicity still continue to bear a high burden 
of the disease given their high prevalence at birth (1 in every 365 live births) in comparison to the 
other ethnic/racial groups that are affected. 
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About 95% of patients with SCD in the USA live well over the age of 18 to 22 years and 
need to transition to an adult healthcare facility. This age group has been associated with 
considerable increase in the use for healthcare and an increase in the risk of death in individuals 
with SCD because of few knowledgeable primary and specialty care providers, poor access to 
facilities offering management, and poor economic status of the majorly affected population.28,30 
In this analysis, I will describe per capita distribution of SCD centers in every state within 
the US and their precise locations in specific counties in relation to the most affected group of 




This study utilized data that is available publicly online and as a result did not require IRB 
review. 
3.1 DATASET DESCRIPTION 
The CDC’s SCD National Resource Directory41 was used as a starting list to identify 
SCD centers in the US. Another directory that was also used is available at this link 45 and was 
used to compare and confirm that all centers were recorded, that contacts and center details were 
added, and that links to the websites updated.  From this list, a comprehensive and systematic 
search via Google from the SCD centers’ websites was conducted. Additional searches for SCD 
Centers not on the list were completed by searching per state using the following search terms; 
Sickle cell disease treatment and research centers in “Name of state”, Sickle cell disease centers 
in “Name of state”, and sickle cell centers in “Name of state”.46. Newly found centers that were 
not included and specified in the SCD National resource Directory46 and link45 were added, and 
those that no longer existed were omitted. Not all of the centers had direct individual websites 
because some were stated as branches or clinics of other major hospitals and centers. 
Center addresses were grouped by state location and www.mapchart.net was used to 
generate visual representation to show the distribution of the SCD centers by state. This website 
was also used to create an additional map showing the precise distribution of the SCD centers by 
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county since the state map only indicated the presence of the centers but was not dependable in 
assessment of the accessibility by the population they serve. 
Concurrently, 3 custom maps were created with each location of the centers using this link.47 
Centers were categorized into 3 groups, with their respective maps; pediatric centers (map)48, adult 
centers (map)49 and centers that offer services to both adult and pediatric patients with SCD 
(map)50. 
Population estimates from U.S. Census Bureau QuickFacts (population, census, April 01, 
2010)51 per state and of county-wide population numbers was used to create tables that helped 
identify the number of SCD centers per state and the proportion of majorly affected ethnic/racial 
groups without ready access to SCD Centers and clinics at the county level. 
Population estimates of the most affected ethnic/racial group, African-Americans,3 was 
used in analyzing per capita and county access to SCD centers since the number of affected 
individuals from other ethnic/racial groups is minimal. The estimated number of African American 
individuals living in the counties that have ≥ 1 SCD center/clinic were categorized as individuals 
with “ease of access” and this was determined by calculating the number of AA in the particular 
counties in comparison to the total number of AA in all the counties in a particular state. This was 





3.2  METHOD OF ANALYSIS 
With a majority of the estimated 100,000 patients in the US with SCD being African -
American, I analyzed the association between the number of SCD centers per state and the 
population size of the group, which was identified using the U.S. Census Bureau QuickFacts 
(population, census, April 01, 2010).51 I used this data to estimate the general average per capita 
access to SCD centers for this population. 
I also assessed the access to SCD centers at the county level by the majorly affected 
population. Population data for counties that have the SCD centers was identified using the U.S. 
Census Bureau QuickFacts (population, census, April 01, 2010).51 The proportion of African-
American population with “ease of access” to the centers was obtained by summing across all 
counties with SCD centers and comparing it to the total population of African-American in the US 







3.3  RESULTS 
3.3.1 Number and distribution of Sickle Cell Disease centers in United States 
The sum total of SCD centers and clinics around the US is 311 with most being pediatric 
centers (71% n= 220) followed by adult centers (22%, n= 68) and lastly centers that offer services 
to both adult and pediatric patients with SCD (7%, n=23). (Figure 2) Several SCD centers have 
branches and clinics in several parts of a city, state, or neighboring states. Thirty-seven SCD 
centers offer services as comprehensive centers with 15 of them offering services to adult patients 
with SCD. For a more detailed list of the sickle cell disease centers found see Appendix B. 
 
 






Table 1 Distribution of Sickle Cell Disease centers categorised by the number of centers per state 
Number of Sickle Cell Disease 
Centers 
Number of States 
represented Percentage representation 
0 7 13.73 
1 10 19.61 
2 5 9.8 
3 6 11.76 
4 3 5.88 
5 1 1.96 
6 1 1.96 
7 1 1.96 
8 5 9.8 
9 2 3.92 
11 2 3.92 
12 2 3.92 
17 2 3.92 
21 1 1.96 
27 1 1.96 
28 1 1.96 




The seven states that do not have an established Sickle cell disease center are Alaska, 
Nevada, Idaho, Wyoming, Montana, Maine, and West Virginia (Figure 2). In the remaining 43 
states and Washington D.C, the number of SCD centers’ distribution ranges between 1- 29 per 
state with an average of 7 centers per state. 
Of the 50 states and Washington D.C., 7 states (13.73%) do not have any SCD center 
identifies through this search, 10 states (19.61%) have only 1 SCD center each and 4 states have 
more than 20 centers each (Table 1). A detailes documentation of the SCD centers per state can be 
found in Table 4 in Appendix A. 
 





The 7 States lacking SCD centers have a small number of AA living in them as per the 
population estimates of the 2010 census data51 (Table 6) and are represented in Figure 4 as grey 
shaded states. For the AA individuals in the remaining 43 states and D.C, the per capita access is 
represented with color intensity indication decreasing with availability of access, light blue 
representing the states with better access and darker blue representing states with limited access to 
SCD centers/clinic. The average per capita access for every one SCD center is 134,800 AA 
individuals per center, with a maximum of 394,772 AA in Georgia and a minimum of 8,760 AA 
in Vermont. (Figure 4). 
 
 
Figure 4 African American per capita access to Sickle Cell Disease centers in the United States 
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3.3.2 County- based Analyses of Sickle cell disease centers’ distribution 
The location of SCD centers at the state level was crude, therefore the number of SCD 
centers by county was investigated and it was found that only 155 out of the 3133 counties in the 
US have more than one SCD center/clinic. Despite them being sparsely distributed, there was 
visible absence of SCD centers in counties in the Northwest region of USA. A bigger proportion 
of SCD centers and clinics is in the Northeast, Mid-Atlantic, Southeast, and part of the Mid-West 








The estimated total number of African American individuals who lack “ease of access” to 
SCD centers in the remaining 2978 counties was categorized per state. “Ease of access” was 
defined as having a SCD center in the county. All counties in Alaska, Idaho, Maine, Montana, 
Nevada, West Virginia, and Wyoming had the highest level of inaccessibility to SCD centers of 
100% each since there are no SCD centers located in those states. On the contrary Washington 
D.C had the lowest rate of inaccessibility of 0% for the AA individuals given that the number of 
centers were more than sufficient to serve the estimated number of individuals in the District. The 
average inaccessibility across states was 53%. For more details see Table 5 in Appendix A. 
3.3.3 Sickle Cell Disease Centers Resource Maps 
Information gathered on the SCD Centers in the US was used to develop resource maps 
(Figure 6, Figure 7, and Figure 8) to be used by researchers and clinicians as a guide on where to 
refer patients with SCD and to aid patients living with SCD in locating centers offering services 
in their area. For ease of access and to simplify the ability of researchers, clinicians, patients and 
their relatives to search for centers in their preferred location, the maps are categorized into three 
groups: pediatric SCD centers, Adult SCD centers and SCD centers offering services to both 
pediatric and adult patients. 
The 220 pediatric SCD centers are presented in the map with blue indicators. There is a 
visible absence of pediatric SCD centers in most parts of the Northwest, and some parts of the 




Figure 6 Snapshot of the map identifying pediatric Sickle Cell Disease centers in the United States 
 
The map with the 68 Adult centers shows a total absence of the centers in the North West 





Figure 7 Snapshot of the map identifying adult Sickle Cell Disease centers in the United States 
 
The 23 SCD centers offering services to both pediatric and adult patients are represented 
in the map with purple indicators and are evidently very few. There is also an evident absence of 




Figure 8 Snapshot of the map identifying centers offering both pediatric and adult  Sickle Cell Disease care in 
the United States 
 
These maps allow for a detailed search and give the name of the center in the search area, 
the contacts of the center and a link that enables an individual to open the center’s website to get 
more information on the center and services they offer. An example of one of the searches is shown 














The developed custom map shows the distribution of SCD centers by county in the US 
(Figure 5) and indicates the geographic distribution of SCD centers, revealing that majority of 
SCD centers are in the West, Mid-Atlantic, and South East regions of the United States. SCD 
centers in the North West, South West, and Mid-west regions of the US are very few and sparsely 
distributed. (Figure 3) The seven states that do not have an established SCD center are all either 
rural and /or mountainous and have a small number of African Americans living in the state in 
comparison to other states. Some states with high numbers of AA do not appear to have sufficient 
SCD centers to offer services to individuals living in them. Most of these states, for example 
Mississippi, are known to have high poverty rates. This therefore means that starting and 
maintaining a SCD center in these areas may be difficult from a funding perspective given the fact 
that SCD centers are not federally sponsored and that they depend on institutional support, 
donations and third party reimbursement for clinical services, which can be low in rural areas.27 
African Americans living in these states may receive care from other qualified providers who are 
not part of the SCD centers, but at some point they may have to travel or be emergently transferred 
to neighboring states that have SCD centers to receive more advanced treatment or tests. As per 
the access per capita results, Washington D.C has sufficient SCD centers to offer care to 
individuals in its territory and possibly serve the neighboring states like Virginia and Maryland. It 
is therefore also important to increase funding towards developing the centers and maintaining the 
ones that already exist to ensure that individuals with SCD can easily access and receive quality 
healthcare services.31 
Telemedicine clinic sites could be one among the possible solutions to the inaccessibility 
and absence of SCD centers in these areas. This helps families save money and are therefore able 
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to afford the purchase of required medicine and food for their members with SCD. Telehealth 
would also play an important role in educating the public, especially the majorly affected African 
American community, on the presentation of the disease and ways of reducing and possibly 
preventing occurrence of complications among these patients with SCD. This will help cut down 
on the costs and expenditure of the families and also improve their quality of life. 34 Teleconsults 
and/or telementoring, like Project ECHO which is an all teach all learn initiative,52 could allow 
healthcare providers in the areas lacking SCD centers with no specialization in management of 
SCD patients to be able to obtain guidance through online communication or educational models 
and mentoring from healthcare providers with expertise in managing patients with SCD.32 
Additionally, states that have a center in ≥ 1 county could organize to have satellite clinics set up 
in other counties without SCD centers, that would work on a certain number of days to have SCD 
healthcare professional specialists visit the clinics to see the patients with SCD. This would aid in 
cutting down on the number of individuals with SCD, especially adult patients, who miss important 
visits/ appointments due to bad terrain, poor infrastructure and transportation services or lack of 
ample time to travel to and from the center without interfering with their work schedule. 
Even though there has been an evident decrease in mortality of patients with SCD over the 
years38, the burden of SCD is still weighing heavily on the African American community.14,15,16,17 
There is need to advocate for more funding and to channel the funding towards the care of 
individuals diagnosed with SCD as well as research studies and clinical trials tailored specifically 
towards individuals diagnosed with SCD from all the affected races/ethnic groups. 
Given the difficulty in estimating the locations of patients with SCD in each state, it is 
important that states continue to assess the needs of this population in their states and ensure that 




This study, looking at distribution of SCD Centers in the US, had several limitations. The 
search strategy was complicated because not all centers used common or expected titles that 
include SCD center or program in their name. Some used names of individuals or different names 
that required a lot more effort in searching for the state. We used key words to search the internet 
but also had to compare what we found with the previously published informational links and 
addresses in the CDC SCD directory (last updated in 2011) and the link (last updated in 1998). 
Therefore, there is a possibility that some centers have been missed in this collection and 
compilation. Given that the SCD center directory that was utilized may have been out of date, 
attempts to contact the CDC publication office to inquire if they had a latest version of the directory 
were not successful. 
Information on the precise representation of SCD patients in the USA was not obtained 
because not all states have readily accessible estimations of SCD patients in their areas of 
jurisdiction. Similarly, the catchment area of the centers may in some areas be larger than the 
counties where they were located, for example, the adult Comprehensive Sickle cell center located 
in Allegheny county, PA regularly manages individuals with SCD from more than 10 counties in 
Pennsylvania as well as a significant number of individuals residing in neighboring states such as 
Ohio and West Virginia.  Therefore, the results of this study may not be accurately representative 
of the healthcare access of patients with SCD in the US. 
In the estimation of ease of access, being in a county with more than one SCD center does 
not necessarily mean that an individual with SCD could easily access it. Other factors like 
infrastructure, transportation system, healthcare insurance and financial ability of the individuals 
contribute to the healthcare access. Example, if an individual with SCD does not live on a bus line 
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or is living in a county without a bus line to the SCD center, the SCD center might not be accessible 
to them. Additionally, individuals with SCD living in a neighboring county might be closer to a 
SCD center if it is located at the border of two counties than others who are in the county with the 
SCD center but living on the extreme end of the county. Cross state borders were also not taken 
into account in this study. This therefore is only an estimate and is not entirely representative of 
the measure of ease of access. 
This study evaluated geographical location but did not entertain or discuss the overall 
structure, capacity and resources that each of the Sickle cell center identified has to care for the 
population they offer services to, thus a follow-up study evaluating their capacity, resources, 
institutional support and presence of, or lack of, standardized approaches for patient care between 
these centers will be complementary to our findings. 
The information used in this study analysis mainly targeted African-Americans, but 
individuals of other racial and ethnic backgrounds can also have SCD. It is therefore not 
representative of all affected individuals and ethnic groups. In addition, we also do not have 
information on outreach SCD centers and centers currently offering telemedicine and telegenetics, 







This study indicated that there are likely inequalities in access to SCD centers in the US 
based on the regional location of an individual and the state they live in. It also indicates that a 
comprehensive up-to-date resource listing all currently functional SCD centers does not exist. 
There is no centralized SCD registry/database that contains demographics and/or health-related 
outcome of all individuals with SCD in all states in the US, though some states do maintain some 
of this information. 
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4.0 SIGNIFICANCE OF THE REVIEW TO PUBLIC HEALTH 
The results of this study point out the fact that the monitoring of a SCD patient’s status is 
not equal to all individuals in the US because it depends on the availability and proximity of a 
SCD center or a healthcare facility offering the services in the area of residence of the affected 
individuals. With the only available directories on SCD centers and facilities being outdated, an 
up-to-date directory on the SCD centers, clinics, and support groups will assist physicians in 
directing patients with SCD for more advanced and expertise management. The resource maps and 
updated directory created in this review are meant make it easier for patients and their families to 
know where to go for healthcare and support services if they are researching centers or if they have 




APPENDIX A: DETAILED TABLES ON SICKLE CELL DISEASE CENTER IN US 
Table 2 State Per capita access of African American population to SCD centers 
STATE 
AA population 
Estimate No. of SCD centers Per Capita Access 
Alabama 1,280,969 8 160,121 
Alaska 26,279 0 - 
Arizona 332,385 4 83,096 
Arkansas 457,799 2 228,900 
California 2,421,507 28 86,482 
Colorado 231,343 1 231,343 
Connecticut 436,040 3 145,347 
Delaware 208,321 1 208,321 
Florida 3,177,421 17 186,907 
Georgia 3,158,175 8 394,772 
Hawaii 29,927 2 14,963 
Idaho 14,108 0 - 
Illinois 1,873,272 12 156,106 
Indiana 641,896 4 160,474 
Iowa 124,901 1 124,901 
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Kansas 174,040 1 174,040 
Kentucky 368,846 7 52,692 
Louisiana 1,486,946 8 185,868 
Maine 22,582 0 - 
Maryland 1,795,575 8 224,447 
Massachusetts 589,287 11 53,572 
Michigan 1,393,593 4 348,398 
Minnesota 371,275 3 123,758 
Mississippi 1,121,638 3 373,879 
Missouri 706,693 6 117,782 
Montana 5,936 0 - 
Nebraska 94,970 2 47,485 
Nevada 278,157 0 - 
New Hampshire 23,696 1 23,696 
New Jersey 1,327,576 21 63,218 
New Mexico 53,539 3 17,846 
New York 3,410,546 29 117,605 
North Carolina 2,116,877 12 176,406 
North Dakota 22,868 1 22,868 
Ohio 1,511,282 9 167,920 
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Oklahoma 292,605 2 146,303 
Oregon 84,284 1 84,284 
Pennsylvania 1,524,285 17 89,664 
Rhode Island 89,468 2 44,734 
South Carolina 1,248,848 5 249,770 
South Dakota 18,726 1 18,726 
Tennessee 1,085,184 11 98,653 
Texas 3,243,777 9 360,420 
Utah 41,458 1 41,458 
Vermont 8,760 1 8,760 
Virginia 1,592,204 27 58,971 
Washington 295,880 8 36,985 
West Virginia 66,708 0 - 
Wisconsin 381,028 3 127,009 
Wyoming 7,327 0 - 









Table 3 Distribution of Sickle cell Disease Centres in USA 
STATE Total counties per state No. of counties with centers 
No. of SCD centers per 
State 
AL 67 5 8 
AK 20 0 0 
AZ 15 2 4 
AR 75 1 2 
CA 58 11 28 
CO 64 3 1 
CT 8 2 3 
DE 3 1 1 
FL 67 8 17 
GA 159 2 8 
HI 5 1 2 
ID 44 0 0 
IL 102 4 12 
IN 92 3 4 
IA 99 1 1 
KS 105 1 1 
KY 120 2 7 
LA 64 4 8 
ME 16 0 0 
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MD 24 3 8 
MA 14 4 11 
MI 83 4 4 
MN 87 1 3 
MS 82 1 3 
MO 115 6 6 
MT 56 0 0 
NE 93 1 2 
NV 17 0 0 
NH 10 1 1 
NJ 21 9 21 
NM 33 3 3 
NY 62 11 29 
NC 100 6 12 
ND 53 1 1 
OH 88 5 9 
OK 77 1 2 
OR 36 1 1 
PA 67 8 17 
RI 5 1 2 
SC 46 4 5 
SD 66 1 1 
TN 95 4 11 
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TX 254 6 9 
UT 29 1 1 
VT 14 1 1 
VA 133 13 27 
WA 39 4 8 
WV 55 0 0 
WI 72 2 3 
WY 23 0 0 
DC 1 1 3 

















Table 4 Number of African Americans in counties with Sickle Cell Disease centers 
STATE Counties with SCD Centers Population Of AA 
No. of SCD 
centers 
Alabama Jefferson 286,433 3 
 
Montgomery 136,012 1 
 
Lee County 32,117 1 
 
Tuscaloosa 63,069 1 
 
Mobile 149,503 2 
Arizona Maricopa 244,295 3 
 
Pima 41,171 1 
Arkansas Pulaski 145,061 2 
California Alameda 166,130 4 
 
Los Angeles 883,674 9 
 
Orange 63,215 2 
 
Placer 6,620 1 
 
San Bernardino 191,310 1 
 
Santa Clara 49,886 2 
 
San Diego 170,242 2 
 
Fresno 53,966 1 
 
Sacramento 154,648 2 
 
San Francisco 45,093 2 
 
Madera 6,336 2 
Colorado Adams, Arapahoe, Douglas 88,297 1 
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Connecticut Hartford 141,254 2 
 
New Haven 131,097 1 
Delaware New Castle 142,158 1 
Florida Orange 261,278 3 
 
Pinellas 101,736 1 
 
Hillsborough 221,261 1 
 
Alachua 50,951 1 
 
Miami-Dade 441,869 5 
 
Duval 266,193 2 
 
Broward 527,916 3 
 
Lee 56,307 1 
Georgia Fulton 409,659 7 
 
Richmond 115,717 1 
Hawaii Honolulu 26,690 2 
Illinois Cook 1,236,333 9 
 
Macon 19,717 1 
 
Rock Island 16,378 1 
 
Champaign 27,749 1 
Indiana Marion 262,887 2 
 
Allen 42,639 1 
 
St. Joseph 36,836 1 
Iowa Johnson 9,816 1 
Kansas Johnson 26,665 1 
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Kentucky Jefferson 166,006 6 
 
Lexington-Fayette 42,596 1 
Louisiana Orleans Parish 206,641 3 
 
Jefferson Parish 122,412 1 
 
Caddo Parish, 127,485 2 
 
East Baton Rouge Parish 207,761 2 
Maryland Baltimore 243,924 6 
 
Prince George's 556,042 1 
 
Montgomery 195,327 1 
Massachusetts Norfolk 53,668 1 
 
Hampden 50,520 1 
 
Suffolk 175,452 8 
 
Worcester 48,712 1 
Michigan Washtenaw 42,409 1 
 
Wayne 704,566 1 
 
Genesee 86,435 1 
 
Kalamazoo 29,539 1 
Minnesota Hennepin 159,035 3 
Mississippi Hinds 179,303 3 
Missouri 
Jackson, Clay, Platte, 
and Cass counties 187,341 2 
 
Boone 15,939 1 
 
St. Louis 249,739 3 
 
 44 
Nebraska Douglas 59,468 2 
New Hampshire Grafton 1,159 1 
New Jersey Essex 328,483 5 
 
Bergen 66,979 1 
 
Camden 110,950 2 
 
Monmouth 47,279 3 
 
Middlesex 97,183 3 
 
Hudson 93,871 2 
 
Mercer 78,800 1 
 
Passaic 74,683 1 
 
Ocean 20,756 2 
 
Union 127,687 1 
New Mexico Bernalillo 23,852 2 
 
Sandoval 3,552 1 
New York New York 282,285 9 
    
    
 
Queens 461,759 3 
 
Kings 846,589 5 
 
Richmond 54,373 1 
 
Westchester 158,502 1 
 
Bronx 603,907 4 
 




Monroe 120,584 1 
 
Nassau 175,479 1 
 
Albany 42,893 1 
 
Onondaga 56,043 1 
North Carolina Durham 98,740 1 
 
Chatham 7,875 1 
 
Orange 15,789 3 
 
Forsyth 96,434 1 
 
Pitt 60,365 2 
 
Mecklenburg 303,477 4 
North Dakota Cass 9,586 1 
Ohio Hamilton 213,431 2 
 
Franklin 276,893 2 
 
Cuyahoga 390,437 3 
 
Montgomery 115,058 1 
 
Lucas 89,688 1 
Oklahoma Oklahoma 113,544 1 
 
Tulsa 65,168 1 
Oregon Multnomah 44,120 1 
Pennsylvania Philadelphia 665,339 8 
 
Allegheny 163,929 3 
 
Chester 30,931 4 
 




Dauphin 126,888 1 
Rhode Island Providence 51,475 2 
South Carolina Charleston 78,333 2 
 
Richland 92,105 1 
 
Beaufort 187,253 1 
 
Greenville 29,040 1 
South Dakota Minnehaha 83,025 1 
Tennessee Shelby 10,338 5 
 
Knox 503,711 1 
 
Hamilton 38,468 2 
 
Davidson 64,937 3 
Texas Harris 171,711 2 
 
Tarrant 818,492 1 
 
Dallas 323,817 3 
 
Williamson 558,881 1 
 
Bexar 31,278 1 
 
Jackson 147,470 1 
Utah Salt Lake 943 1 
Vermont Chittenden 22,652 1 
Virginia Norfolk 3,914 1 
 
Richmond 102,220 5 
 
Stafford 2,739 2 
 




Fairfax 823 3 
 
Loudoun 114,663 1 
 
Albemarle 25,297 5 
 
Augusta 9,600 1 
 
Culpeper 3,466 1 
 
Rockingham 6,817 1 
 
Frederick 1,908 1 
 
Roanoke 3,680 3 
 
Campbell 5,912 1 
Washington King 8,117 2 
 
Spokane 135,187 3 
 
Benton 9,424 1 
 
Pierce 3,153 2 
Wisconsin Milwaukee 257,784 2 
 
Dane 26,844 1 











Table 5 Number of African Americans in Counties without Sickle Cell Disease centers 
STATE 
Number of AA 
in all Counties 
Number of AA in counties 
without SCD Centers 
Percentage of AA without 
close access to SCD 
Center 
Alabama 1,280,969 613,836 48 
Alaska 26,279 26,279 100 
Arizona 332,385 46,918 14 
Arkansas 457,799 312,738 68 
California 2,421,507 630,386 26 
Colorado 231,343 143,046 62 
Connecticut 436,040 163,689 38 
Delaware 208,321 66,162 32 
Florida 3,177,421 1,249,911 39 
Georgia 3,158,175 2,632,800 83 
Hawaii 29,927 3,237 11 
Idaho 14,108 14,108 100 
Illinois 1,873,272 573,096 31 
Indiana 641,896 299,533 47 
Iowa 124,901 115,084 92 
Kansas 174,040 147,375 85 
Kentucky 368,846 160,245 43 
Louisiana 1,486,946 822,647 55 
Maine 22,582 22,582 100 
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Maryland 1,795,575 800,281 45 
Massachusetts 589,287 260,935 44 
Michigan 1,393,593 530,644 38 
Minnesota 371,275 212,240 57 
Mississippi 1,121,638 942,335 84 
Missouri 706,693 253,675 36 
Montana 5,936 5,936 100 
Nebraska 94,970 35,501 37 
Nevada 278,157 278,157 100 
New Hampshire 23,696 22,538 95 
New Jersey 1,327,576 280,906 21 
New Mexico 53,539 26,134 49 
New York 3,410,546 479,466 14 
North Carolina 2,116,877 1,534,198 72 
North Dakota 22,868 13,282 58 
Ohio 1,511,282 425,774 28 
Oklahoma 292,605 113,894 39 
Oregon 84,284 40,164 48 
Pennsylvania 1,524,285 480,408 32 
Rhode Island 89,468 11,135 12 
South Carolina 1,248,848 857,425 69 
South Dakota 18,726 8,389 45 
Tennessee 1,085,184 306,357 28 
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Texas 3,243,777 1,362,896 42 
Utah 41,458 18,806 45 
Vermont 8,760 4,847 55 
Virginia 1,592,204 1,281,169 80 
Washington 295,880 86,882 29 
West Virginia 66,708 66,708 100 
Wisconsin 381,028 96,400 25 
Wyoming 7,327 7,327 100 
Washington DC 276,793 0 0 
TOTAL 41,547,602 18,893,898 53 
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APPENDIX B: SICKLE CELL DISEASE CENTERS/CLINICS IN THE US 
STATE CENTER ADDRESS, CONTACT AND LINK 
Alabama Comprehensive 
Sickle Cell Center - 
UAB 
1802 6th Avenue, South 
North Pavilion, Room 2512 
Birmingham, AL 35294  








1600 7th Ave. 
S. Birmingham, AL 35233 
(205) 638-9100 
https://www.childrensal.org/hematology 
Alabama Montgomery Site at 
UAB Montgomery 
2055 East South Boulevard 






Alabama Opelika Site at East 
Alabama Medical 
Center Clinic 
2501 Village Professional Dr 
Opelika, AL 36801 
(334) 528-1070 




850 Peter Bryce Boulevard 
Tuscaloosa, AL 35401 
(205) 348-1770 
https://umc.ua.edu/university-medical-center/ 
Alabama The Kirkland Clinic 
(TKC) | UAB 
2000 6th Avenue 











Alabama Strada Patient Care 
Center 







Alabama Mastin Patient Care 
Center 
Suite 102 2451 University Hospital Dr. 
AL 36617;(251) 470-5890 
https://www.usahealthsystem.com/services/sickle-cell-care 
Alaska No Center 
 
Arizona Sickle Cell 





Arizona Phoenix Children's 
Hospital - Main  
1919 E. Thomas Rd 




Arizona Phoenix Children's 
Specialty Care - 
Tucson 
5983 E. Grant Rd. 








5131 E. Southern Ave. 














Arkansas Sickle Cell Disease 
Program | Arkansas 
Children's 
1 Children's Way 





Arkansas UAMS Adult 
Sickle Cell Clinical 
Program  
4301 W. Markham 








California Alta Bates Summit 
Medical Center | 













California Children's Hospital 
Los Angeles 





California CHOC Children's 
Main Campus - 
Orange 






Los Angeles County Harbor 1000 W Carson Street 





California Kaiser Permanente 
Oakland Medical 
Center 
Kaiser Foundation Hosp 275 W Macarthur Boulevard 
Oakland, CA 94611; 
(510) 752-1000; 
California Kaiser Permanente 
Roseville Medical 
Center 





California Kaiser Permanente 
West Los Angeles 
Medical Center 
Kaiser Found Hosp Wla 6041 Cadillac Avenue Los 





California LAC+USC Medical 
Center 




California LAC+USC Medical 
Center 
1240 Mission Rd., Rm. 911 Los Angeles, California 90033 
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California Loma Linda 
University 
Children's Hospital 
Loma Linda University 11234 Anderson Street,Suite A 
Loma Linda, CA 92354; 
(909) 651-1422; 
https://lluch.org/services/specialty-team-centers 
California Lucile Packard 
Children's Hospital 
Stanford 




California Miller Children's & 
Women's Hospital 
Long Beach 
Long Beach Mem Med Ctr 2801 Atlantic Avenue Long 




California Rady Children's 
Hospital San Diego 





California Saint Agnes 
Medical Center 
Saint Agnes Medical Center 1303 E Herndon Avenue 





California Sutter Medical 
Center, Sacramento 




California UC Davis Medical 
Center 
UC Davis Medical Center 2315 Stockton Boulevard 
Sacramento, CA 95817; 
(916) 734-2011; 
https://health.ucdavis.edu/medicalcenter/ 
California U.C. Irvine Medical 
Center 
101 City Drive South Bldg. 29A, Rt. 81 Orange, California 
92668; 
(714) 456-6615 OR (714)-880-7812; 
http://www.ucihealth.org/medical-services/blood-disorders 
California UCLA Mattel 
Children's Hospital 
at Ronald Reagan 
Regents of The University of 757 Westwood Plaza Los 




California UCSF Benioff 
Children's Hospital 
Oakland 






California UCSF Benioff 
Children's Hospital 
San Francisco 
UCSF Medical Center 505 Parnassus Avenue San 
Francisco, CA 94143; 
(415) 476-1000; 
http://www.ucsfmissionbayhospitals.org/children/ 
California Valley Children's 
Hospital 
Valley Childrens Hospital 9300 Valley Childrens Place 
Madera, CA 93636; 
(559) 353-3000; 
https://www.valleychildrens.org/# 




San Francisco Gen Hosp 1001 Potrero Avenue San 
Francisco, CA 94110; 
(415) 821-8200; 
https://zuckerbergsanfranciscogeneral.org/ 
California Stanford Children's 
Hospital  
Stanford Children's Hospital Sickle Cell Disease Center 
735 Welch Rd. Palo Alto, California 94303 ; 
(415) 497-8238 ; 
https://www.stanfordchildrens.org/en/topic/default?id=sick
le-cell-disease-in-children-90-P02327 
California Valley Children’s 
Hospital of Central 
California  





California Highland Hospital 
Sickle Cell Disease 
Center 
1411 E. 31st St. Oakland, California 94602; 
(510) 437-4251; 




UC San Diego Health 200 West Arbor Drive San Diego, 
CA 92103; 
(858) 657-7000 OR  (800) 926-8273; 
https://health.ucsd.edu/Pages/default.aspx 
California City of Hope 
Medical Center  




   
Colorado Colorado Sickle 
Cell Treatment and 
Research Center 
 CU Anschutz Education II South 13121 East 17th Avenue 









Connecticut Children's Hartford 282 Washington Street 






Connecticut Yale New Haven 
Health | Adult 
Sickle Cell Clinic 





Connecticut New England 
Sickle Cell Institute 
(NESCI) 
Carole and Ray Neag Comprehensive Cancer center Uconn 
Health Main Building 300 Uconn Health Boulevard 









Nemours/Alfred I. duPont Hospital for Children 1600 




Florida Sickle Cell Disease 
Program - Arnold 
Palmer Hospital 






Florida Sickle Cell 
Program - Johns 
Hopkins All 
Children's Hospital 









Medicine | USF 
Health - University 
of South Florida 








1600 SW Archer RD Gainesville, FL 32608; 
(352) 273-9120; 
https://ufhealthjax.org/pediatric-sickle-cell/ 
Florida Sickle cell 
program-University 
of Miami| Miller 
school of medicine 






Florida Pediatric Sickle 
Cell Program| UF 
Health C.B. 
Mclntosh Center - 
University of 
Florida Jacksonville 
 555 West 11th Street Jacksonville, FL 32206; 
(904) 244-4472; 
https://ufhealthjax.org/pediatric-sickle-cell/ 
Florida Foundation for 
Sickle Cell Disease 
Research 




Florida Golisano Children’s 
Hospital of 
Southwest Florida 




Florida Holtz Children’s 
Hospital (Pediatric 
care) 
1611 NW 12th Avenue Miami, FL 33136; 
(305) 585-5437; 
https://jacksonhealth.org/holtz/oncology/ 
Florida Jackson Memorial 
Hospital (Adult 
care) 
1611 NW 12th Avenue Miami, FL 33136; 







cell day hospital 
|Memorial 
Healthcare System 







care Program | 
Miami Children's 










Children’s Clinic | 
Specialty Care, 
Orlando 





Children’s Clinic | 








Florida Nemours Children's 
Hospital, Orlando 








of Miami School of 
Medicine Sickle 
Cell Center 






Sickle Cell Center | 
Grady Memorial 
Hospital 




Georgia Sickle Cell Disease 
Program | Aflac 
Cancer and Blood 
Disorders Center - 











Georgia Sickle Cell Disease 
Program | Aflac 
Cancer and Blood 
Disorders Center - 




1405 Clifton Road NE Atlanta, GA 30322; 
(404) 785-1200; 
https://www.choa.org/locations/egleston-hospital#location 
Georgia Sickle Cell Disease 
Program | Aflac 













Georgia Sickle Cell Center - 
Medical College of 
Georgia | Augusta 
University 
Walter L. Shepeard Building 989 St. Sebastian Way 
Augusta, GA  30912; 
(706) 721-2171- Adult OR 706-721-0174- Pediatric; 
https://www.augusta.edu/centers/blood-disorders/sickle-
cell/ 
Georgia Sickle Cell Disease 
Research - Emory 
University 








1513 Cleveland Avenue, Bldg. 500 East Point, GA. 30344; 
(404) 752-1000; 
http://morehousehealthcare.com/specialties/pediatrics.html 
Georgia Winship Cancer 
Institute | Emory 
University Clifton 
Campus 




Hawaii Hawaii Sickle cell 
Disease Project - 
State of Hawaii, 
Department of 
Health 
741 Sunset Avenue Honolulu, HI 96816; 




Hawaii Hawaii Community 
Genetics| Kapiolani 
Medical Center for 
women and 
Children 




Idaho No Center 
 
Illinois Sickle cell program UI Health(Comprehensive care program) 
Illinois Acute Care Center 
at the UI Health 
University of Illinois Hospital 1740 W. Taylor St. Suite 5E 




Illinois Pediatric Sickle 
Cell Program at UI 
Health  
Outpatient Care Center 1801 W. Taylor St. Suite 2E 




Illinois The S.T.A.R. Clinic 
at UI Health - 
Transitional Care 
University of Illinois Hospital 1740 W. Taylor St. Suite 5E 






Illinois Adult Care Center 
at the UI Health 
University of Illinois Hospital 1740 W. Taylor St. Suite 5E 




Illinois Sickle Cell Disease 
Program| Ann & 
Robert H. Lurie 
Children's Hospital 
of Chicago 




Illinois Rush University 
Children's Hospital 




Illinois Rush University 
Medical Center  
1620 W. Harrison St. Chicago, IL 60612; 
(888) 352-RUSH (7874) 
Illinois Comer Children's | 
Uchicago Medicine 







Illinois OSF Children's 
Hospital of Illinois 
- Sickle Cell Clinic 




Illinois OSF Children's 
Hospital of Illinois 
- Sickle Cell Clinic 




Illinois OSF Children's 
Hospital of Illinois 
- Sickle Cell Clinic 




Illinois Pediatric Sickle 
Program | La 
Rabida Children's 
Hospital  
6501 South Promontory Drive Chicago, IL 60649; 
(773) 256-5759; 
https://larabida.org/program/sickle-cell-disease/ 
Indiana The Indiana 
Hemophilia & 
Thrombosis Center 
8326 Naab Road Indianapolis, IN 46260; 
(317) 871-0000; 
https://www.ihtc.org/ 
Indiana Lutheran Children's 
Hospital 
7950 West Jefferson Boulevard Fort Wayne, Indiana 





Indiana Riley Pediatric 
Sickle Cell Center- 
Riley Hospital for 
Children | Riley 
Outpatient Center 
702 Barnhill Drive, 3rd Floor Indianapolis, Indiana 46201; 
(317) 944-2143 OR (800) 248-1199; 
https://www.rileychildrens.org/health-info/sickle-cell-
disease 





615 North Michigan Street, 6th Floor South Bend, Indiana 
46601; 







Care Program| UI 
Health Care 
Department of 
Pediatrics - Stead 
Family Children's 
Hospital 








Kansas University of 
Kansas Cancer care 
center 




Kentucky Sickle Cell Disease 
Program | Norton 
Children's 
Louisville, Ky. 




Kentucky Sickle Cell 
Treatment Program| 
UL school of 
Medicine 













Kentucky Norton Cancer 
Institute Downtown 




Kentucky Norton Women’s & 
Children’s Hospital 
campus 
 Norton Medical Plaza 2, Suite 405 3991 Dutchmans Lane 
Louisville, KY 40207; 
(502) 899-3366; 
Kentucky Norton Audubon 
Hospital campus  
Norton Medical Plaza West, Suite 405 2355 Poplar Level 
Road Louisville, KY 40217; 
(502) 636-7845; 
Kentucky Norton Cancer 
Institute – 
Brownsboro  
4950 Norton Healthcare Blvd. Louisville, KY 40241; 
(502) 394-6350; 
Kentucky Hematology/Oncol




UK Chandler Hospital - Pavilion HA 800 Rose St. 




Louisiana Tulane Sickle Cell 




Louisiana Tulane Sickle Cell 
Center of Southern 
Louisiana- Adult & 
Transitional Sickle 
Cell Clinic at the 








Louisiana Pediatric Sickle 
Cell Clinic Tulane 
Lakeside Hospital 
for Women & 
Children - 4th floor 




Louisiana Sickle Cell Disease 
Program at Feist-
Weiller Cancer 
Center |LSU Health 
Shreveport, Main 
Campus 
1405 Kings Highway, Shreveport, LA 71103 (use for GPS) 





Louisiana Hematology & 
Oncology | 
Children’s Hospital 
New Orleans  




Louisiana St. Jude Children's 
Resesarch hospital| 
Baton Rouge 
Affiliate Clinic at 
Our Lady of the 





















Lady of the Lake 











Maine No Center 
 





22 S. Greene St, Baltimore, MD 21201; 






















600 North Wolfe Street Baltimore, MD 21287; 
(410) 955-5000- Maryland (855) 695-4872 Outside of 
Maryland OR +1-410-502-7683 International; 
https://www.hopkinsmedicine.org/health/conditions-and-
diseases/sickle-cell-disease 
Maryland The Sickle Cell 
Infusion 
Center|Sickle Cell 
Center for Adults at 
John Hopkins 
Hospital 
1800 Orleans Street- Park 1 Baltimore, MD 21287; 
(410) 614-0676; 
https://www.hopkinsmedicine.org/hematology/sicklecell/ 
Maryland Kennedy Krieger 
Institute 






Maryland Children's National Comprehensive Sickle Cell Disease Program 
Maryland Children's National 
Prince George's 
County | Blood 
Disoreders(Hemato
logy) 




Maryland Children's National 
Montgomery 
County 
9850 Key West Avenue Rockville, Maryland 20850; 
(301) 765-5400 OR (800) 787-0243; 
https://childrensnational.org/visit/locations-and-
directions/outpatient-centers/montgomery-county 
Maryland The Sidney 
Kimmel 
Comprehensive 
Cancer Center | 
John Hopkins 
Medicine 














Massachusetts Brigham and 
Women's Hospital| 
Sickle Cell Disease 
Clinic 




Massachusetts Mass. Gen Hospital 
Sickle cell disease 
clinic 
55 Fruit Street Boston, MA  02114; 
(617) 726-2737; 
https://www.massgeneral.org/condition/sickle-cell-disease 
Massachusetts Boston Children's 
Hospital sickle cell 
Disease Program 
















Massachusetts BU Center of 
Excellence in 
Sickle Cell Disease 









oncology | Bay 
state Health 





Massachusetts Benign Hematology 
Program at Tufts 
Medical Center 






Massachusetts UMass Memorial 
Medical Center 
Sickle Cell Disease 
Clinic 







Massachusetts Boston Medical 
Center|Pediatric  
Hematology 
850 Harrison Ave Boston, MA 0218 Yawkey Ambulatory 





Michigan C.S Mott Children's 
Hospital| university 
of Michigan 




Michigan Sickle Cell Center 




3950 Beaubien Boulevard Detroit, MI 48201; 
(313)-745-KIDS ; 
https://www.childrensdmc.org/services/sickle-cell-center 
Michigan Hurley Medical 
Center Pediatric 
Sickle Cell Clinic  




Michigan Bronson Pediatric 
Hematology/Oncol
ogy 





and Sickle Cell 
Program |Children's 
Minnesota 

















Minnesota University of 
Minnesota Masonic 
Children’s Hospital| 
Blood and Marrow 
Transplant (BMT) 
Unit 




Mississippi Children's of 
Mississippi| Center 





2500 N. State St. Jackson, MS 39216; 




Mississippi University of 
Mississippi Medical 
2500 N. State St. Jackson, MS 39216 ;; 
 
 82 
Center Sickle Cell 
Center 
Mississippi Jackson Hinds 
Comprehensive 
Health Center 
3502 West Northside Drive Jackson, MS 39213; 
(601) 362-5321; 
https://www.jackson-hinds.com/adult-med 
Missouri Sickle Cell Disease 
Program| Children's 
Mercy 






Missouri Designated Sickle 
Cell Center | 
Cardinal Glennon 
Children's Hospital 




Missouri St. Louis Children's 
Hospital 
One Children’s Place St. Louis, MO 63110; 
(314) 454-6000 OR (800) 678-5437; 
https://www.stlouischildrens.org/conditions-
treatments/sickle-cell-disease-program 
Missouri  Truman Medical 
Centers/University 




Health Sickle Cell 
Center 
https://www.trumed.org/services/sickle-cell-center/ 
Missouri University of 
Missouri School of 
Medicine | Child 
Health Divisions 











1 Barnes-Jewish Hospital Plaza St. Louis, MO 63110; 
(314) 362-7216.; 
Montana No Center 
 
Nebraska Children's Hospital 








Nebraska University of 
Nebraska Medical 
Center | Oncology 
























Disorders - Sickle 
Cell Anemia 
Center| Children's 
Hospital of New 
Jersey at Newark 
Beth Israel Medical 
Center 




New Jersey Pediatric 
Hematology at the 
Children's Cancer 
30 Prospect Ave, Hackensack, NJ 07601; 






Children's Health at 




New Jersey Children's Hospital 
of Philadelphia, 
New Jersey Section 
of 
Hematology/Oncol
ogy Specialty Care 
Center 




New Jersey Frederick B. 
Cohen, MD, 
Comprehensive 
Cancer and Blood 
Disorder Center -
Newark Beth Israel 
Medical Center 




New Jersey Pediatric 
Hematology - 




Neptune | at  the 
Rutgers Cancer 





New Jersey Regional 
Comprehensive 









New Jersey Pediatric 
hematology 
Program | Cooper 
University Health 
Care 
Three Cooper Plaza Camden, NJ 08103; 
(856) 342-2001 OR (800) 826-6737; 
https://www.cooperhealth.org/services/pediatric-
hematology 




355 Grand Street Jersey City, NJ 07302; 
(888) 724-7123 OR (201) 915-2000; 
https://www.rwjbh.org/treatment-
care/pediatrics/conditions-treatments/pediatric-cancer/ 
New Jersey hematology centers 
|Jersey City 
Medical Center 



















1 Hamilton Health Place Hamilton, NJ 08690; 
(888) 724-7123 OR (609) 586-7900; 
https://www.rwjbh.org/treatment-
care/pediatrics/conditions-treatments/pediatric-cancer/ 
New Jersey Children’s Hospital 
of New Jersey at 
Newark Beth Israel 
Medical Center The 
Valerie Fund 
Children’s Centers 
for Cancer and 
Blood Disorders 
201 Lyons Avenue at Osborne Terrace Newark, NJ 07112; 
(973) 926-7161; 
https://www.thevaleriefund.org/sickle-cell-patient-program 
New Jersey K. Hovnanian 
Children’s Hospital 
at Jersey Shore 
Medical Center 













for Cancer and 
Blood Disorders 




New Jersey University of 
Medicine and 







150 Bergen St, Newark, NJ 07103; 
(973) 972-0658; 
http://www.uhnj.org/directory/pediatrics/hema_onco.htm 










Institute of New 
Jersey|RWJ 
Barnabas Health 




at Saint Peter’s 
University Hospital 




New Jersey Valerie Fund 
Center at St. 
Joseph’s Children’s 
Hospital 
703 Main Street Paterson, NJ 07503; 
(973) 754-2500; 
https://www.stjosephshealth.org/pedshemonc 





99 Highway 37 West Toms River, NJ 08755; 
(732) 557-8000 OR (888) 724-7123; 
https://www.rwjbh.org/treatment-
care/pediatrics/conditions-treatments/pediatric-cancer/ 
New Jersey J. Phillip Citta 
Regional Cancer 
Center at 








New Mexico University of New 
Mexico 
Comprehensive 
Cancer Center  
















Oncology at Mount 
Sinai Kravis 
Children’s Hospital 
1468 Madison Avenue Annenberg Building, 4th Floor 




New York Hematology and 
Medical Oncology 
service at The 
Blavatnik Family – 
Chelsea Medical 
325 West 15th Street New York, NY 10011; 





Center at Mount 
Sinai  
New York Derald H. 
Ruttenberg 
Treatment Center, 
part of The Tisch 
Cancer Institute at 
The Mount Sinai 
Hospital 








2715 30th Avenue Astoria, NY 11102; 
(718) 932-1000; 
https://www.mountsinai.org/locations/queens/care/cancer 









New York Mount Sinai-Union 
Square 
10 Union Square East Suites 4A, 4B, 4C, 4D New York, 
NY 10003; 





New York NYC Health + 
Hospitals/Harlem| 
Pediatric center 




New York NYC Health + 
Hospitals/Harlem| 
Adult care 




New York NYC Health + 
Hospitals/Kings 
County 
451 Clarkson Avenue Brooklyn, NY 11203; 
(718) 245-3325 OR 718-245-3131; 
https://www.nychealthandhospitals.org/kingscounty/our-
services/specialties/ 
New York NYC Health + 
Hospitals/Queens 




82-68 164th Street Jamaica, New York 11432, Pavilion, 




New York Division of 
Hematology/Oncol












New York Sanford R. Nalitt 
Institute for Cancer 




division of Staten 
Island University 
Hospital 









n Stanley Children's 
Hospital 




New York Comprehensive 
Pediatric Sickle 







and Medical Center 






New York Sickle Cell Disease 






100 Woods RoadValhalla, NY 10595; 
(914) 493-7000; 
https://www.mariafarerichildrens.org/sickle-cell-disease 
New York Montefiore Sickle 






Family Care Center 4th Floor, Clinic 460 3444 Kossuth 
Avenue Bronx, NY 10467; 




New York Sickle Cell & 
Hemoglobinopathy 
Center of WNY at 
John R. Oishei 
Children's Hospital 
Roswell Park Comprehensive Cancer Center Elm & 




New York Golisano Children's 
Hospital | Pediatric 
Hematology/Oncol
ogy 













New York Sickle Cell 
Disorders and the 
Sickle Cell 
Program|Montefior
e and Albert 
Einstein College of 
Medicine-Family 
Care Center 








New York Sickle Cell 
Disorders and the 
Sickle Cell 
Program|Montefior
e and Albert 
Einstein College of 
Medicine-
Montefiore Practice 
1695 Eastchester Road 2nd Floor, Oncology/Hematology 





New York NYU Winthrop 

























s Hospital at 
Albany Medical 
Center 




















1910 Nostrand Ave Brooklyn, NY 11226; 
(718) 284-4440; 
New York Sickle 
Cell/Thalassemia 
Program at 

























Sickle Cell Center| 
Duke University 
Hospital 
40 Duke Medicine Cir Clinic 2N Durham, NC 27710-
4000; 





















Program at the 
University of North 
Carolina| Division 
of Hematology and 
Oncology 
Houpt Building, 3rd Floor 170 Manning Drive, CB# 7305 














101 Manning Drive in Chapel Hill Chapel Hill, NC 27514 
(pediatric clinic); 












Medical Center Boulevard Winston-Salem, NC 27157; 












Sickle Cell Center 






sickle cell treatment 
center at James and 
Connie Maynard 
Children’s Hospital 
at Vidant Medical 
Center  




















ogy Clinic -  Sickle 
Cell Program 






















Cancer & Blood 
Disorders, a facility 
of Atrium Health at 
Levine Children's 
Hospital 







PMG Hematology / 
Oncology at 
Presbyterian Rust 












PMG Hematology / 
Oncology at 
Presbyterian 











North Dakota Meritcare Roger 
Maris Cancer 
Center 






Sickle Cell Center 
at Cincinnati 
Children’s 
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026; 
(513) 636-4200 OR (800) 344-2462; 
https://www.cincinnatichildrens.org/service/s/sickle-cell 





460 W. 10th Avenue Columbus, OH 43210; 

















Ohio Seidman Cancer 
Center - Adult 
Sickle Cell Disease 
Clinic | University 
Hospitals 
11100 Euclid Avenue Cleveland, OH 44106; 
(216) 844-1582 ; 
https://www.uhhospitals.org/services/cancer-
services/benign-hematologic-disorders/adult-sickle-cell 
Ohio  University of 
Cincinnati Medical 
Center - Adult 
Sickle Cell Center 




Ohio Dayton Children’s 
comprehensive care 
for kids with sickle 
cell disease 




Ohio Cleveland Clinic - 
Sickle cell Disease 




Ohio Department of 
Pediatric 














Adult Sickle Cell 
Clinic | ProMedica 
Toledo Hospital 




Oklahoma Jimmy Everest 




Hospital at OU 
Medicine 
O.U. Children’s Physicians Building 1200 Childrens Ave 






gy clinic at The 
Children's Hospital 
at Saint Francis 







- Pediatric Blood 
Disorders 
700 S.W. Campus Drive Portland, Oregon 97239;503-346-




















3500 Civic Center Blvd. Philadelphia, PA 19104; 
(215) 590-1000 OR (215) 590-3423; 
https://www.chop.edu/centers-programs/sickle-cell-center 
Pennsylvania UPMC Adult 
Sickle Cell Disease 
Program 
Hillman Cancer Center William  Pavilion, 2nd Floor 5115 





Pennsylvania Pediatric Sickle 
Cell Program - 
Children's Hospital 
Pittsburgh 






Sickle cell Disease 





Pennsylvania Abramson Cancer 
Center Perelman 
4th Floor West - 
Hospital of the 
University of 
Pennsylvania 
3400 Civic Center Boulevard Philadelphia, PA 19104 










of University of 
Pennsylvania 
3400 Civic Center Boulevard Philadelphia, PA 19104 









ogy West Chester | 
Chester County 
Hospital 







ogy Exton| Chester 
County Hospital 
720 West Lincoln Highway The Commons at Oaklands 






ogy Kennett Square 
of Chester County 
Hospital 


















Pennsylvania Abramson Cancer 
Center Radnor of 



















Pennsylvania Abramson Cancer 
Center Valley 
Forge 
Penn Medicine Valley Forge 1001 Chesterbrook Boulevard 




Pennsylvania Marian Anderson 
Comprehensive 
Sickle Cell Care 
and Research 
160 E Erie Ave Philadelphia, PA 19134; 











Sickle Cell Anemia 








Pennsylvania Sickle Cell Center 




200 Lothrop Street Pittsburgh, PA 15213; 
(412) 648-3181; 
https://sicklecell.pitt.edu/about-the-center/ 
Pennsylvania Nemours duPont 
Pediatrics, 
Philadelphia 
833 Chestnut St. E., Suite 300 - Specialty Care 






Rhode Island pediatric 
hematology/oncolo
gy at Hasbro 
Children's Hospital 




Rhode Island Sickle Cell 
Multidisciplinary 
Clinic of the 
Lifespan Cancer 
Institute 
Ambulatory Patient Center (APC Building) 593 Eddy 







Health Sickle cell 
Center 








- Sickle Cell Clinic 
7 Richland Medical Park Dr. Columbia, SC 29203; 






Sickle Cell Clinic | 
Beaufort Memorial 
Campus 
989 Ribaut Road, Suite 103 (with Infusions Services) 











Sickle Cell Disease 
Program of Prisma 
Health | (located 
within the BI-LO 
Charities Children’s 
Cancer Center) 







Sickle cell Care 





South Dakota Sanford Children’s 
Hematology and 
Oncology | Sanford 
Children's Hospital 
Sioux Falls 





Tennessee St. Jude Children's 
Pediatric Sickle 
Cell Program 





Tennessee Center for Sickle 
Cell Disease at 
UTHSC 
College of Medicine 956 Court Avenue, Suite D324 





Sickle Cell Center | 
Methodist Le 
Bonheur Healthcare 
1325 Eastmoreland, Suite 101 Memphis, TN  38104; 
(901) 516-8785 OR (901) 516-8188; 
https://www.methodisthealth.org/healthcare-
services/sickle-cell-center/ 
Tennessee East Tennessee 
Children's 
Hospital | Pediatric 
hematology/Oncolo
gy 




Tennessee Erlanger Health 
System | Medical 
Oncology/Hematol
ogy 





Tennessee T.C Thompson 
Children's Hospital 
- Erlanger Health 
910 Blackford Street 5th Floor Massoud Building 




System | Childhood 









848 Adams Avenue Memphis, TN  38103; 
(866) 870-5570; 
https://www.lebonheur.org/services/hematology 
Tennessee Diggs-Kraus Sickle 
Cell Center - 
Regional One 
Health| Affiliated 
medical center of 
UTHSC 

















Tennessee Meharry Sickle 
Cell Center - Adult 
Sickel Cell Clinic 





Children's Center of 
Excellence in 
Sickle Cell Disease 




Texas Texas Children's 
Hospital Cancer 
and Hematology 
Centers - Sickle 
Cell Program 




Texas UT Physicians 
Comprehensive 
Sickle Cell Center 
Plaza Medical Center 1200 Binz, Suite 850 Houston, TX 
77004; 




Texas Sickle Cell 
Program at Cook 
Children's Sickle 









Texas UT Southwestern 
Medical Center 
Comprehensive 
Sickle cell Center 
5323 Harry Hines Blvd. Dallas, TX 75390; 
(214) 645-8300 OR  (817) 882-2700; 
https://utswmed.org/conditions-treatments/sickle-cell/ 










Texas Children’s Blood & 
Cancer Center 
(CBCC) | Dell 
Children’s Medical 
Center 

















Texas Children's Hospital 
of San Antonio 
Cancer and Blood 
Disorders Center | 
Christus Health - 
Baylor College of 
Medicine 















Hospital - Cancer, 
Blood and Marrow 
Clinic 
100 N Mario Capecchi Dt Salt Lake City, UT 84113; 
(801) 662-4700 OR (801) 662-1000(After hour contact); 
https://intermountainhealthcare.org/primary-
childrens/programs-specialties/cancer 
Vermont University of 
Vermont Children's 
111 Colchester Avenue Main Campus, Specialty Center 
Burlington,  Vermont  05401; 
 
 117 






Virginia Children's Hospital 
of The King's 
Daughters 
Comprehensive 
Sickle cell program 





Virginia VCU Health Sickle 
Cell Program 
57 N 11th St, Richmond, VA 23298; 
(800) 762-6161; 
https://www.vcuhealth.org/services/sickle-cell-program 
Virginia Children's Hospital 
of Richmond 
(CHoR) at VCU | 
ASK Pediatric 
Hematology and 
Oncology Clinic  
Children's Pavilion 1000 East Broad Street Richmond,VA 
23219; 












Virginia VCU Massey 
Cancer Center 
401 College Street, Box 980037 Richmond, Virginia 
23298-0037; 
(804) 828-0450 
 E-mail: AskMassey@vcu.edu; 
https://www.massey.vcu.edu/ 
Virginia VCU Medical 
Center North 
Hospital 
1300 E. Marshall Street Richmond,VA 23219; 
https://www.vcuhealth.org/locations/location-details?id=16 
Virginia Ambulatory Care 
Center | VCU 
Health 
417 N. 11th Street Richmond,VA 23219; 
https://www.vcuhealth.org/locations/location-details?id=10 
Virginia Comprehensive 
Sickle Cell Disease 
Program at 
Children's National 
















Fairfax CCBD 8081 Innovation Park Dr, Suite 765, 
Building B, Fairfax, Virginia, 22031; 
(571) 472-1717; 
https://psvcare.org/specialty/cancer-and-blood-disorders 
Virginia Inova Hematology 
Oncology - Fairfax 





Virginia Inova Hematology 
Oncology - Fair 
Oaks 




Virginia Pediatric Specialists 
of Virginia - 
Ashburn 





Virginia UVA Cancer 
Center - 
comprehensive  








Virginia Emily Couric 
Clinical Cancer 
Center 




Virginia UVA Cancer 
Center Pantops 





Virginia UVA Cancer 
Center Augusta 

















Virginia Stem Cell 
Transplant Clinic 
Emily Couric Clinical Cancer Center Third Floor 1240 Lee 




Virginia UVA Children's 
comprehensive 
sickle cell clinic 
 
Virginia UVA Pediatric 
Hematology/Oncol
ogy 
Battle building Fifth Floor 1204 W. Main St. 




Virginia UVA Pediatrics 
Harrisonburg 
McGaheysville 




Virginia UVA Pediatrics 
Harrisonburg 






Virginia UVA Pediatrics 
Specialty Care 
Winchester 

















Virginia Carilion Children's 
Hospital 













Virginia Carilion Roanoke 
Memorial Hospital 






Washington Sickle cell program 
| Seattle Children's - 
Odessa Brown 
Children's Clinic 




Washington Seattle Cancer Care 
Alliance (SCCA) 
825 Eastlake Ave E PO Box 19023 Seattle WA 98109-
1023; 
(855) 557-0555 ; 
https://www.seattlecca.org/diseases/sickle-cell-disease 





















Clinic - Richland 




Washington Sacred Heart 
Children's Hospital 




Washington Providence Sacred 
Heart Medical 
Center 




Washington Mary Bridge 
Children's Hospital 










311 South L Street West Wing, First Floor Tacoma, WA 
98405; 





West Virginia No Centers 
 
Wisconsin MACC Fund 











Wisconsin Adult Sickle Cell 
Clinic at Froedtert 
Hospital 
9200 W. Wisconsin Ave. Milwaukee, WI 53226; 
(414) 805-2220; 
https://www.froedtert.com/sickle-cell-disease 
Wisconsin Pediatric Sickle 
Cell Anemia Clinic 
| American Family 
Children's Hospital 



















Hospital - Center 












Sickle Cell Disease 
Program at 
Children's National 
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